Patents Assigned to OCULARIS PHARMA, LLC
  • Aqueous ophthalmic solutions of phentolamine and medical uses thereof
    Patent number: 9795560
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: October 24, 2017
    Assignee: Ocularis Pharma, LLC
    Inventor: Alan Meyer
  • Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
    Patent number: 9789088
    Abstract: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: October 17, 2017
    Assignee: Ocularis Pharma, LLC
    Inventor: Alan Meyer
  • Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
    Patent number: 9089560
    Abstract: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: July 28, 2015
    Assignee: Ocularis Pharma, LLC
    Inventor: Alan Meyer
  • Night vision composition
    Patent number: 8979809
    Abstract: A method for optimizing pupil size in individuals suffering from excessive pupillary dilation in dim light as well as through medication is disclosed. Alpha 1 antagonist is applied in an eye drop formulation to the eye, resulting in reduced pupil size in dim light, but less reduction in pupil size in bright light.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: March 17, 2015
    Assignee: Ocularis Pharma, LLC
    Inventor: Gerald Horn
  • Ophthalmic formulations including selective alpha 1 antagonists
    Patent number: 8889112
    Abstract: Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: November 18, 2014
    Assignee: Ocularis Pharma, LLC
    Inventor: Gerald Horn
  • AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF
    Publication number: 20140221445
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 7, 2014
    Applicant: OCULARIS PHARMA, LLC
    Inventor: Alan Meyer
  • METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISUAL PERFORMANCE
    Publication number: 20140221446
    Abstract: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 7, 2014
    Applicant: Ocularis Pharma, LLC
    Inventor: Alan Meyer